Logo image of ALCLS.PA

CELLECTIS (ALCLS.PA) Stock Fundamental Analysis

EPA:ALCLS - Euronext Paris - Matif - FR0010425595 - Common Stock - Currency: EUR

2.23  +0.33 (+17.49%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ALCLS. ALCLS was compared to 67 industry peers in the Biotechnology industry. ALCLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALCLS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALCLS had negative earnings in the past year.
ALCLS had a positive operating cash flow in the past year.
ALCLS had negative earnings in each of the past 5 years.
In the past 5 years ALCLS reported 4 times negative operating cash flow.
ALCLS.PA Yearly Net Income VS EBIT VS OCF VS FCFALCLS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

ALCLS's Return On Assets of -14.12% is fine compared to the rest of the industry. ALCLS outperforms 62.69% of its industry peers.
ALCLS has a Return On Equity (-41.34%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -14.12%
ROE -41.34%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ALCLS.PA Yearly ROA, ROE, ROICALCLS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of ALCLS (4.64%) is comparable to the rest of the industry.
ALCLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCLS.PA Yearly Profit, Operating, Gross MarginsALCLS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALCLS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALCLS has more shares outstanding
The debt/assets ratio for ALCLS has been reduced compared to a year ago.
ALCLS.PA Yearly Shares OutstandingALCLS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ALCLS.PA Yearly Total Debt VS Total AssetsALCLS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

ALCLS has an Altman-Z score of -0.80. This is a bad value and indicates that ALCLS is not financially healthy and even has some risk of bankruptcy.
ALCLS has a Altman-Z score (-0.80) which is comparable to the rest of the industry.
ALCLS has a debt to FCF ratio of 4.88. This is a neutral value as ALCLS would need 4.88 years to pay back of all of its debts.
ALCLS's Debt to FCF ratio of 4.88 is amongst the best of the industry. ALCLS outperforms 83.58% of its industry peers.
A Debt/Equity ratio of 0.65 indicates that ALCLS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.65, ALCLS is in line with its industry, outperforming 47.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.88
Altman-Z -0.8
ROIC/WACCN/A
WACC6.31%
ALCLS.PA Yearly LT Debt VS Equity VS FCFALCLS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ALCLS has a Current Ratio of 1.73. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.
ALCLS has a Current ratio (1.73) which is in line with its industry peers.
A Quick Ratio of 1.73 indicates that ALCLS should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.73, ALCLS perfoms like the industry average, outperforming 47.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.73
ALCLS.PA Yearly Current Assets VS Current LiabilitesALCLS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.54% over the past year.
Looking at the last year, ALCLS shows a very strong growth in Revenue. The Revenue has grown by 357.43%.
The Revenue has been growing by 16.44% on average over the past years. This is quite good.
EPS 1Y (TTM)45.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325%
Revenue 1Y (TTM)357.43%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%85.12%

3.2 Future

Based on estimates for the next years, ALCLS will show a very negative growth in Earnings Per Share. The EPS will decrease by -75.28% on average per year.
Based on estimates for the next years, ALCLS will show a very strong growth in Revenue. The Revenue will grow by 30.02% on average per year.
EPS Next Y-235.09%
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%
EPS Next 5YN/A
Revenue Next Year63.01%
Revenue Next 2Y30.93%
Revenue Next 3Y12.51%
Revenue Next 5Y30.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALCLS.PA Yearly Revenue VS EstimatesALCLS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
ALCLS.PA Yearly EPS VS EstimatesALCLS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALCLS. In the last year negative earnings were reported.
Also next year ALCLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALCLS.PA Price Earnings VS Forward Price EarningsALCLS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

89.55% of the companies in the same industry are more expensive than ALCLS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.7
EV/EBITDA N/A
ALCLS.PA Per share dataALCLS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

ALCLS's earnings are expected to decrease with -75.28% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%

More info and screens

0

5. Dividend

5.1 Amount

ALCLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTIS

EPA:ALCLS (7/25/2025, 7:00:00 PM)

2.23

+0.33 (+17.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)07-31 2025-07-31
Inst Owners18.59%
Inst Owner ChangeN/A
Ins Owners2.82%
Ins Owner ChangeN/A
Market Cap223.73M
Analysts84.62
Price Target6.63 (197.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)82%
Min EPS beat(2)18.3%
Max EPS beat(2)145.69%
EPS beat(4)4
Avg EPS beat(4)73.41%
Min EPS beat(4)6.42%
Max EPS beat(4)145.69%
EPS beat(8)6
Avg EPS beat(8)27.22%
EPS beat(12)9
Avg EPS beat(12)23.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)108.7%
Min Revenue beat(2)55.84%
Max Revenue beat(2)161.56%
Revenue beat(4)4
Avg Revenue beat(4)91.56%
Min Revenue beat(4)50.31%
Max Revenue beat(4)161.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.56
P/FCF 13.7
P/OCF 11.41
P/B 2
P/tB 2.02
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)0.16
FCFY7.3%
OCF(TTM)0.2
OCFY8.76%
SpS0.63
BVpS1.11
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.12%
ROE -41.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.64%
FCFM 25.96%
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.88
Debt/EBITDA N/A
Cap/Depr 19.36%
Cap/Sales 5.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.73
Altman-Z -0.8
F-Score7
WACC6.31%
ROIC/WACCN/A
Cap/Depr(3y)12.8%
Cap/Depr(5y)139.39%
Cap/Sales(3y)9.66%
Cap/Sales(5y)33.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325%
EPS Next Y-235.09%
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%
EPS Next 5YN/A
Revenue 1Y (TTM)357.43%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%85.12%
Revenue Next Year63.01%
Revenue Next 2Y30.93%
Revenue Next 3Y12.51%
Revenue Next 5Y30.02%
EBIT growth 1Y35.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.14%
EBIT Next 3Y-33.24%
EBIT Next 5Y-29.24%
FCF growth 1Y174.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y192.9%
OCF growth 3YN/A
OCF growth 5YN/A